Last updated: March 2, 2026
Overview of the Drug
Iopamidol-250 is an iodine-based contrast agent used in X-ray imaging procedures like computed tomography (CT). The formulation in a plastic container enhances portability and ease of use. Iopamidol-250 is marketed primarily for diagnostic imaging, with a focus on vascular and tissue imaging.
Market Size and Growth Projections
Global Contrast Agent Market
The contrast agent market, encompassing both iodine-based and gadolinium-based products, reached approximately USD 3.9 billion in 2022. The market is expected to grow at a CAGR of around 4.5% through 2030, driven by increasing imaging procedures and technological advances.
Iodine-based Contrast Agents Segment
Iodine-based contrast agents dominate the market, with a valuation of USD 2.1 billion in 2022. Key products include iohexol, iodixanol, and iopamidol. Iopamidol holds a significant share within this segment, estimated at 25%, with revenues of around USD 525 million in 2022.
Regional Market Breakdown
| Region |
Market Share (2022) |
Growth Rate (2023-2030) |
Notes |
| North America |
40% |
4.0% |
Mature market, high imaging volume |
| Europe |
25% |
4.5% |
Strong healthcare infrastructure |
| Asia-Pacific |
20% |
6.0% |
Rapidly expanding imaging services |
| Latin America |
8% |
4.0% |
Growing healthcare access |
| Middle East & Africa |
7% |
4.5% |
Increasing adoption of CT scans |
Drivers of Market Growth
- Aging populations increasing demand for diagnostic imaging.
- Advancements in imaging technology requiring contrast agents.
- Rising healthcare expenditure in emerging markets.
- Elevated concerns over contrast agent safety and improved formulations.
Competitive Landscape
Major manufacturers include GE Healthcare, Bracco Imaging, and Bayer HealthCare. Iopamidol-250 marketed in plastic containers is primarily supplied by regional and specialty pharmaceutical firms.
| Company |
Market Share (Est.) |
Key Products |
Focus Areas |
| GE Healthcare |
40% |
Omnipaque, Visipaque |
Broad imaging solutions |
| Bracco Imaging |
35% |
Iohexol, Iopamiro |
Specialized contrast agents |
| Bayer Healthcare |
15% |
Ultravist, Isovue |
Global presence, innovation |
| Others |
10% |
Various regional brands |
Niche and specialty products |
Pricing and Revenue Outlook
Pricing Structure
- Average wholesale price per vial (250 mgI/mL) in a plastic container: USD 15–25.
- Dose volume: generally 50–150 mL per injection.
- Estimated cost per full dose: USD 750–3,750 depending on volume and market.
Revenue Forecast
Assuming a conservative market penetration with 10% of the iodine contrast segment and an annual utilization of 10 million doses globally:
| Year |
Estimated Doses (millions) |
Revenue (USD millions) |
Notes |
| 2023 |
1 |
150–250 |
Initial adoption stage |
| 2025 |
3 |
450–750 |
Increased clinical use |
| 2027 |
5 |
750–1,250 |
Market expansion |
| 2030 |
8 |
1,200–2,000 |
Market maturity |
Regulatory and Adoption Factors
- Regulatory approvals influence market access; approvals in major markets like FDA (U.S.) and EMA (Europe) are required.
- Preference for plastic containers hinges on safety, convenience, and cost.
- Patient safety concerns, notably allergic reactions and renal impairment, influence product formulation and adoption.
Challenges and Opportunities
Challenges
- Competition from ultrasound and MRI modalities reducing contrast need.
- Stringent regulations on iodine contrast safety.
- Limited differentiation among products; price sensitivity dominates purchasing decisions.
Opportunities
- Development of lower-osmolarity formulations to reduce adverse events.
- Incremental market growth via expanding imaging procedures in emerging economies.
- Partnership opportunities with hospital networks and imaging centers.
Financial Risks
- Regulatory delays can postpone product launches and revenue.
- Price competition limits margins.
- Patent expirations for comparator products may pressure pricing strategies.
Key Takeaways
- The global contrast agent market, especially iodine-based agents like Iopamidol-250, exhibits steady growth driven by increased diagnostic imaging, aging populations, and technological advances.
- Market share is dominated by large players, with regional firms filling niche segments.
- Pricing remains sensitive, with unit cost strongly influenced by formulation, container type, and regional health policies.
- Revenue projections indicate moderate growth potential, with a focus on expanding clinical use and emerging markets.
- Challenges include regulatory hurdles and competitive pressures; opportunities exist in formulation improvements and global outreach.
5 FAQs
1. What is the primary driver for Iopamidol-250's market growth?
The increase in diagnostic imaging procedures globally, supported by aging populations and technological advancements, drives market growth.
2. How does plastic container packaging influence market acceptance?
Plastic containers improve safety, portability, and ease of administration, promoting adoption in clinical settings.
3. What regulatory considerations impact market entry?
Approvals from agencies like the FDA and EMA are necessary; safety profile and manufacturing standards influence approval timing and market access.
4. Who are the key competitors in this segment?
Major players include GE Healthcare, Bracco Imaging, and Bayer HealthCare, occupying substantial shares of the iodine contrast agent market.
5. What are the main cost factors for Iopamidol-250 in clinical use?
Pricing depends on formulation, container type, regional pricing policies, and competition. The average wholesale cost per vial ranges from USD 15 to 25.
References
[1] MarketsandMarkets. (2023). Contrast Agents Market by Type, Application, and Region. Retrieved from https://www.marketsandmarkets.com
[2] Grand View Research. (2022). Contrast Media Market Size, Share & Trends. Retrieved from https://www.grandviewresearch.com
[3] U.S. Food and Drug Administration. (2022). Safety of Iodinated Contrast Agents. https://www.fda.gov
[4] European Medicines Agency. (2022). Clinical Evaluation of Contrast Agents. https://www.ema.europa.eu
